AI Article Synopsis
- A study was conducted from September 2022 to April 2023 to evaluate how COVID-19 vaccines affect the risk of infection in children under 5 years old.
- The results showed no significant difference in infection risk between vaccinated and unvaccinated children.
- Although the vaccines are effective in preventing severe illness, they may not prevent the actual infection of the virus in young kids.
Article Abstract
To understand how coronavirus disease 2019 vaccines impact infection risk in children <5 years, we assessed risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from September 2022 to April 2023 in 3 cohort studies. There was no difference in risk by vaccination status. While vaccines reduce severe disease, they may not reduce SARS-CoV-2 infections in naïve young children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpids/piae121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.
PLoS Pathog
January 2025
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
The continued evolution of SARS-CoV-2 variants capable of subverting vaccine and infection-induced immunity suggests the advantage of a broadly protective vaccine against betacoronaviruses (β-CoVs). Recent studies have isolated monoclonal antibodies (mAbs) from SARS-CoV-2 recovered-vaccinated donors capable of neutralizing many variants of SARS-CoV-2 and other β-CoVs. Many of these mAbs target the conserved S2 stem region of the SARS-CoV-2 spike protein, rather than the receptor binding domain contained within S1 primarily targeted by current SARS-CoV-2 vaccines.
View Article and Find Full Text PDFAtmospheric pressure plasma jet for respiratory face masks decontamination and re-use: Considerations on microbiological efficacy, material impact and product lifecycle.
PLoS One
January 2025
European Commission, Joint Research Centre (JRC), Ispra, Italy.
Disposable filtering face piece respirators (FFRs) are not approved for reuse as standard of care. However, lessons learnt from the SARS-CoV-2 pandemic, FFRs decontamination and reuse may be needed as crisis capacity strategy to ensure availability in medical facilities. We studied a decontamination methodology based on atmospheric pressure plasma technology, which allows for rapid, contact-free decontamination without utilisation of harmful chemicals, and suitable to access small pores and microscopic filters openings.
View Article and Find Full Text PDFAgeing and inflammation limit the induction of SARS-CoV-2-specific CD8+ T cell responses in severe COVID-19.
JCI Insight
January 2025
CNRS UMR 5164, INSERM ERL 1303, ImmunoConcEpT, University of Bordeaux, Bordeaux, France.
CD8+ T cells are critical for immune protection against severe COVID-19 during acute infection with SARS-CoV-2. However, the induction of antiviral CD8+ T cell responses varies substantially among infected people, and a better understanding of the mechanisms that underlie such immune heterogeneity is required for pandemic preparedness and risk stratification. In this study, we analyzed SARS-CoV-2-specific CD4+ and CD8+ T cell responses in relation to age, clinical status, and inflammation among patients infected primarily during the initial wave of the pandemic in France or Japan.
View Article and Find Full Text PDFRegulation and Compliance in Telemedicine: Viewpoint.
J Med Internet Res
January 2025
Doxy.me Research, Doxy.me, Inc, Charleston, SC, United States.
The US COVID-19 Public Health Emergency ended on May 11, 2023. Lawmakers and regulators extended some flexibilities while they deliberate effective long-term telemedicine policy. Here, we discuss critical challenges in telemedicine compliance and regulation grounded in scholarly literature and current events.
View Article and Find Full Text PDFDelay discounting predicts COVID-19 vaccine booster willingness.
Cogn Res Princ Implic
January 2025
Department of Psychology and Centre for Integrative and Applied Neuroscience, York University, 4700 Keele St., Toronto, ON, M3J 1P3, Canada.
Developing ways to predict and encourage vaccine booster uptake are necessary for durable immunity responses. In a multi-nation sample, recruited in June-August 2021, we assessed delay discounting (one's tendency to choose smaller immediate rewards over larger future rewards), COVID-19 vaccination status, demographics, and distress level. Participants who reported being vaccinated were invited back one year later (n = 2547) to report their willingness to receive a booster dose, along with reasons for their decision.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!